(BLFE) Skin Cancer Treatment Announced 9/2

Pink Lady

2004-09-10 02:15:23 UTC

Actually, I have been waiting for the results to be made public from this
company and am extremely excited to see their results!!! A member of my
family died from cancer, and I hope that if I ever need such a treatment
like Bio-Life shows that they have, I would hope that I would have access to
their product.

Thanks for bringing this company to other people's attention. I am going to
go buy some shares of what I think will soon not be a penny stock anymore.

Thank you - Pink Lady

Post by Spidermon
Related Quotes
Sym. Price Chg.
BLFE Trade
News 0.18 0.01
I think this stock could really do something. Comments?
Bio-Life Labs Announces First Public Presentation of Data on Flagship Skin
Cancer Product, Carcinoderm
September 02, 2004 12:43:00 (ET)
LOS ANGELES, Sep 2, 2004 (BUSINESS WIRE) -- Bio-Life Labs, Inc. (BLFE,
Trade) today announced the presentation of data on the Company's first
forthcoming product, Carcinoderm(TM), a topical treatment that destroys
skin cancer cells in a one-time application without harming surrounding
healthy tissue. The data was presented in an August 13 speech at the 56th
Annual Meeting of the Pacific Dermatologic Association (PDA) in Newport
Beach, California.
In her presentation regarding future topical treatment options for skin
cancers, Karen F. Han, M.D., Ph.D., a certified clinical dermatologist at
the Palo Alto Medical Foundation, communicated FDA-conforming research by
Dr. David Karam, M.D., Ph.D., that described Carcinoderm as "acting only
on tumor cells in a receptor-specific fashion" in "a single application
causing primary necrosis within 90 minutes." In describing Dr. Karam's
current "open-label trial on over 900 basal cell carcinoma, squamous cell
carcinoma and malignant melanoma" patients, her speech relayed "88%
post-treatment negative biopsies showing no active cancer cells in all
categories."
"Should it prove as effective as early trials indicate, and if
dermatologists can be convinced to use it, I think that Carcinoderm will
dramatically change the way we approach skin cancer," said Dr. Han, who
foresees its use as an alternative to surgery.
The American Cancer Society estimates that during 2004 approximately one
million new cases of basal cell or squamous cell carcinoma and about
59,350 new cases of malignant melanoma, the deadliest type of skin cancer,
will be diagnosed. The ACS further estimates that skin cancer will claim
the lives of approximately 9,800 Americans, 7,900 as a result of melanoma.
Since 1997 the incidence of new melanoma cases in the U.S. has increased
at an average of more than 5% per year, one of the highest growth rates
for any type of cancer. By 2000 there were over 510,000 living skin cancer
patients in the U.S. who had been diagnosed with melanoma. Although death
rates from basal cell and squamous cell carcinomas are low, the ACS
indicates that these cancers can cause considerable damage and
disfigurement if left untreated. Global skin cancer statistics are equally
alarming. The World Health Organization indicates that, in 2000, the
number of newly diagnosed cases of melanoma was 132,600, with 37,000
deaths reported.
About Bio-Life Labs
Bio-Life, Labs, Inc. (www.biolifelabs.com) is a research-driven
biotechnology company focused on discovery, development, manufacturing,
and commercialization of breakthrough treatments for cancer, diabetes
mellitus, and hepatitis C. Its first product candidate, Carcinoderm(TM),
is a topical treatment that is designed to destroy skin cancer cells in
patients diagnosed with basal cell carcinoma, squamous cell carcinoma, and
malignant melanoma in a one-time application without harming surrounding
healthy tissue. Carcinoderm is currently being studied in what the Company
believes are FDA-conforming clinical trials with patients who have
biopsy-confirmed cases in all three categories of skin cancer.
Bio-Life Labs' corporate headquarters is in Los Angeles, California; its
research and development facility is located in the El Paso, Texas area.
Bio-Life Labs, Inc. cautions that statements included in this press
release that are not a description of historical facts are forward-looking
statements. The inclusion of these statements should not be regarded as a
representation by Bio-Life Labs that any of its plans will be achieved.
Actual results may differ materially from those set forth in this release
due to the risks and uncertainties inherent in Bio-Life Labs' business
including, without limitation, statements about: difficulties or delays in
research, development, testing, obtaining regulatory approval, producing
and marketing its technologies and products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that could
delay or prevent product development or commercialization, or that could
result in recalls or product liability claims; the scope and validity of
patent protection for its products; its ability to meet product
development objectives; competition from other pharmaceutical or
biotechnology companies; its ability to obtain additional financing to
support its operations; its ability to attract and retain experienced
scientists and management; as well as other risks detailed in Bio-Life's
Securities and Exchange Commission filings. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and Bio-Life Labs undertakes no
obligation to revise or update this news release to reflect events or
circumstances after the date hereof.
SOURCE: Bio-Life Labs, Inc.